Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo

In Vivo

Volumn 23, Issue 2, 2009, Pages 237-244

  Shen, Jie ^a   Li, Ronghui ^a   Li, Gang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Decoy ODN; Glioma; In vivo; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; STAT3 PROTEIN; STAT3 PROTEIN DECOY OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE TARGETING; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO GENE TRANSFER; MAJOR CLINICAL STUDY; MOUSE; NICK END LABELING; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES; STAT3 TRANSCRIPTION FACTOR;

EID: 64549129578     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Levy DE and Darnell: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662, 2002.
2. Ehret GB, Reichenbach P, Schindler U, Horvath CM, Fritz S, Nabholz M and Bucher: DNA binding specificity of different STAT proteins: Comparison of in vitro specificity with natural target sites. J Biol Chem 276: 6675-6688, 2001.
3. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA and Haque SJ: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21: 8403-8413, 2002.
4. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofen M and Barton A: Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Ther 3: 1183-1191, 2004.
5. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A and Jove R: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513, 2001.
6. Alvarez JV, Grenlinch H, Sellers WR, Meyerson M and Frank DA: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66: 3162-3168, 2006.
7. Qiu Z, Huang C, Sun J, Qiu W, Zhang J, Li H, Jiang T, Huang K and Cao J: RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci 98: 1099-1106, 2007.
8. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF and Rubin Grandis J: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. PNAS 100: 4138-4143, 2003.
9. Alan JD, Morishita R, Kaneda Y, Lee SJ, Kwon KY, Choi SY, lee KU, Park JY, Moon IJ, Park JG, Yoshizumi M, Ouchi Y and Lee IK: Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on Vascular Smooth Muscle Cell proliferation in vitro and neointimal formation in vivo. Circulation Research 90: 1325-1332, 2002.
10. Crinelli R, Bianchi M, Gentilini L and Magnani M: Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res 30: 2435-2443, 2002.
11. Morishita R, Tomita N, Kaneda Y and Ogihara T: Molecular therapy to inhibit NF-KB activation by transcription factor decoy oligonucleotides. Current Opinion in Pharmacology 4: 139-146, 2004.
12. Tomita T, Kunugiza Y, Tomita N, Takano H, Morishita R, Kaneda Y and Yoshikawa H: E2F decoy oligodeoxynucleotide ameliorates cartilage invasion by infiltrating synovium derived from rheumatoid arthritis. Int J Mol Med 18: 257-65, 2006,
13. Gu JH, Li G, Sun T, Su YH, Zhang XL, Shen J, Tian ZG and Zhang J: Blockage of STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 89: 9-17, 2008.
14. Sun X, Zhang J, Wang L and Tian Z: Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262: 201-213, 2008.
15. Zhang X, Zhang J, Wang L, Wei H and Tian Z: Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 7: 149, 2007.
16. Xi S, Gooding WE and Rubin Grandis J: In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24: 970-979, 2005.
17. Morishita R, Tomita N, Kaneda Y and Ogihara T: Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Curr Opin Pharmacol 4: 139-146, 2004.
18. Schaefer LK, Ren Z, Fuller GN and Schaefer TS: Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21: 2058-2065, 2002.
19. Konnikova L, Kotecki M, Kruger MM and Cochran BH: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3: 150, 2003.
20. Shimizu H, Nakagami H, Tsukamoto I, Morita S, Kunugiza Y, Tomita T, Yoshikawa H, Kaneda Y, Ogihara T and Morishita R: NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene Ther 13: 933-941, 2006.
21. Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N, Sakonjo H, Makino H, Kaneda Y, Ogihara T and Morishita R: Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 10: 356-364, 2003.